Neurent Medical Ltd. et al.

Neurent Medical Ltd. is a privately held medtech company headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts. Founded in 2015 by David Townley and Brian Shields, the company is venture-backed and has raised significant capital, including a €62.5 million ($74 million) Series C financing round in February 2026. As of March 2026, Neurent Medical had 76 employees.

Neurent Medical specializes in developing innovative, minimally invasive, non-surgical treatments for chronic inflammatory sino-nasal diseases, particularly chronic rhinitis. Its flagship product, the NEUROMARK® System, utilizes proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, aiming to provide durable symptom relief from chronic rhinitis through an in-office procedure. The company received FDA 510(k) clearance for NEUROMARK in 2021 and for a next-generation system in 2025, and opened a new manufacturing facility in Ireland in June 2025 to meet demand.

Neurent Medical Ltd. demonstrates the posture of an operating company actively defending its intellectual property. The company is listed as a defendant in one tracked case, "Aerin Medical Inc. v. Neurent Medical Ltd. et al.," which is an Inter Partes Review (IPR) proceeding at the Patent Trial and Appeal Board (PTAB). This indicates that Neurent Medical is challenging the patentability of its own technology or patents it relies upon, rather than asserting patents against others.

The specific PTAB cases, IPR2025-01124 and IPR2025-01126, were filed by Aerin Medical Inc. in June 2025 and challenge the patentability of Neurent Medical's patents related to neuromodulation devices for treating rhinitis. These proceedings reflect a dispute between two operating companies in the nasal treatment technology space. A related U.S. District Court case in Delaware also involved these parties and concerned nasal treatment technologies.